(Q45423860)

14 December 2017

title

Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin (English)

1 reference

14 December 2017

vaccinia virus

1 reference

Agnes Jones-Trower

1

1 reference

14 December 2017

Alonzo Garcia

2

1 reference

14 December 2017

Clement A Meseda

3

1 reference

14 December 2017

Yong He

4

1 reference

14 December 2017

Carol Weiss

5

1 reference

14 December 2017

Arunima Kumar

6

1 reference

14 December 2017

Jerry P Weir

7

1 reference

14 December 2017

Michael Merchlinsky

8

1 reference

14 December 2017

language of work or name

English

0 references

publication date

13 September 2005

1 reference

14 December 2017

number of pages

13

1 reference

based on heuristic

inferred from page(s)

published in

Virology

1 reference

14 December 2017

volume

343

1 reference

14 December 2017

issue

1

1 reference

14 December 2017

page(s)

128-140

1 reference

Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin

14 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Dose-dependent neutralizing-antibody responses to vaccinia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

A luminescent ruthenium complex for ultrasensitive detection of proteins immobilized on membrane supports

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Pathogenesis and potential antiviral therapy of complications of smallpox vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Vaccinia virus transcription

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Cysteine scanning mutagenesis at 40 of 76 positions in villin headpiece maps the F-actin binding site and structural features of the domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Primary induction of human CD8+ cytotoxic T lymphocytes and interferon-gamma-producing T cells after smallpox vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Smallpox vaccination: a review, part II. Adverse events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Neutralizing and protective antibodies directed against vaccinia virus envelope antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Repression of vaccinia virus Holliday junction resolvase inhibits processing of viral DNA into unit-length genomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

The looming threat of bioterrorism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Identification of a vaccinia virus penetration protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Experience of anti-vaccinia immunoglobulin in the United Kingdom.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

The formation and function of extracellular enveloped vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Identification of antigenic determinants by polyclonal and hybridoma antibodies induced during the course of infection by vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Identification of the gene encoding vaccinia virus immunodominant protein p35.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

Mapping and nucleotide sequence of the vaccinia virus gene that encodes a 14-kilodalton fusion protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.008

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2005.08.008

1 reference

14 December 2017

1 reference